- Label RSS
Drug Label Info
Safety
- Report Adverse Events
- FDA Safety Recalls
- Presence in Breast Milk
Related Resources
- Medline Plus
- Clinical Trials
- PubMed
- All Citations
- Adverse Effects
- Therapeutic Use
- Pharmacology
- Clinical Trials
- Biochemical Data Summary
More Info For This Drug
- View Labeling Archives
- RxNorm
- Get Label RSS Feed
- View NDC Code(s)NEW!
- Contains inactivated NDC Code(s)
NDC Code(s): 21695-123-15, 21695-123-30, 21695-123-60, 21695-123-90 - Packager: Rebel Distributors Corp
- This is a repackaged label.
- Source NDC Code(s): 60793-136
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Drug Label Information
Updated January 4, 2011
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
View All Sections
- Description
SKELAXIN® (metaxalone) is available as an 800 mg oval, scored pink tablet.
Chemically, metaxalone is 5-[(3,5- dimethylphenoxy) methyl]-2-oxazolidinone. The empirical formula is C12H15NO3, which corresponds to a molecular weight of 221.25. The structural formula is:
Metaxalone is a white to almost white, odorless crystalline powder freely soluble in chloroform, soluble in methanol and in 96% ethanol, but practically insoluble in ether or water.
Each tablet contains 800 mg metaxalone and the following inactive ingredients: alginic acid, ammonium calcium alginate, B-Rose Liquid, corn starch and magnesium stearate.
- Clinical Pharmacology
Mechanism of Action
The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
Pharmaco*kinetics
The pharmaco*kinetics of metaxalone have been evaluated in healthy adult volunteers after single dose administration of SKELAXIN under fasted and fed conditions at doses ranging from 400 mg to 800 mg.
Absorption
Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours. Doubling the dose of SKELAXIN from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known.
The single-dose pharmaco*kinetic parameters of metaxalone in two groups of healthy volunteers are shown in Table 1.
Table 1: Mean (%CV) Metaxalone Pharmaco*kinetic Parameters Dose (mg) Cmax (ng/mL) Tmax (h) AUC∞ (ng•h/mL) t½(h) CL/F (L/h) 4001 983 (53) 3.3 (35) 7479 (51) 9.0 (53) 68 (50) 8002 1816 (43) 3.0 (39) 15044 (46) 8.0 (58) 66 (51) 1Subjects received 1x400 mg tablet under fasted conditions (N=42) 2Subjects received 2x400 mg tablets under fasted conditions (N=59)
Food Effects
A randomized, two-way, crossover study was conducted in 42 healthy volunteers (31 males, 11 females) administered one 400 mg SKELAXIN tablet under fasted conditions and following a standard high-fat breakfast. Subjects ranged in age from 18 to 48 years (mean age = 23.5 ± 5.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased Cmax by 177.5% and increased AUC (AUC0-t, AUC∞) by 123.5% and 115.4%, respectively. Time-to-peak concentration (Tmax) was also delayed (4.3 h versus 3.3 h) and terminal half-life was decreased (2.4 h versus 9.0 h) under fed conditions compared to fasted.
In a second food effect study of similar design, two 400 mg SKELAXIN tablets (800 mg) were administered to healthy volunteers (N=59, 37 males, 22 females), ranging in age from 18-50 years (mean age = 25.6± 8.7 years). Compared to fasted conditions, the presence of a high fat meal at the time of drug administration increased Cmax by 193.6% and increased AUC (AUC0-t, AUC∞) by 146.4% and 142.2%, respectively. Time-to-peak concentration (Tmax) was also delayed (4.9 h versus 3.0 h) and terminal half-life was decreased (4.2 h versus 8.0 h) under fed conditions compared to fasted conditions. Similar food effect results were observed in the above study when one SKELAXIN 800 mg tablet was administered in place of two SKELAXIN 400 mg tablets. The increase in metaxalone exposure coinciding with a reduction in half-life may be attributed to more complete absorption of metaxalone in the presence of a high fat meal (Figure 1).
Distribution, Metabolism, and Excretion
Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
Pharmaco*kinetics in Special Populations
Age:
The effects of age on the pharmaco*kinetics of metaxalone were determined following single administration of two 400 mg tablets (800 mg) under fasted and fed conditions. The results were analyzed separately, as well as in combination with the results from three other studies. Using the combined data, the results indicate that the pharmaco*kinetics of metaxalone are significantly more affected by age under fasted conditions than under fed conditions, with bioavailability under fasted conditions increasing with age.
The bioavailability of metaxalone under fasted and fed conditions in three groups of healthy volunteers of varying age is shown in Table 2.
Table 2: Mean (%CV) Pharmaco*kinetic Parameters Following Single Administration of Two 400 mg SKELAXIN Tablets (800 mg) under Fasted and Fed Conditions Younger Volunteers Older Volunteers Age (years) 25.6 ± 8.7 39.3 ± 10.8 71.5 ± 5.0 N 59 21 23 Food Fasted Fed Fasted Fed Fasted Fed Cmax (ng/mL) 1816 (43)
3510 (41)
2719 (46)
2915 (55)
3168 (43)
3680 (59)
Tmax (h) 3.0 (39)
4.9 (48)
3.0 (40)
8.7 (91)
2.6 (30)
6.5 (67)
AUC0-t (ng·h/mL) 14531 (47)
20683 (41)
19836 (40)
20482 (37)
23797 (45)
24340 (48)
AUC∞ (ng·h/mL) 15045 (46)
20833 (41)
20490 (39)
20815 (37)
24194 (44)
24704 (47)
Gender:
The effect of gender on the pharmaco*kinetics of metaxalone was assessed in an open label study, in which 48 healthy adult volunteers (24 males, 24 females) were administered two SKELAXIN 400 mg tablets (800 mg) under fasted conditions. The bioavailability of metaxalone was significantly higher in females compared to males as evidenced by Cmax (2115 ng/mL versus 1335 ng/mL) and AUC∞ (17884 ng·h/mL versus 10328 ng·h/mL). The mean half-life was 11.1 hours in females and 7.6 hours in males. The apparent volume of distribution of metaxalone was approximately 22% higher in males than in females, but not significantly different when adjusted for body weight. Similar findings were also seen when the previously described combined dataset was used in the analysis.
Hepatic/Renal Insufficiency:
The impact of hepatic and renal disease on the pharmaco*kinetics of metaxalone has not been determined. In the absence of such information, SKELAXIN should be used with caution in patients with hepatic and/or renal impairment.
- Indications and Usage
SKELAXIN (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.
- Contraindications
Known hypersensitivity to any components of this product.
Known tendency to drug induced, hemolytic, or other anemias.
Significantly impaired renal or hepatic function.
- Warnings
SKELAXIN may enhance the effects of alcohol and other CNS depressants.
- Precautions
Metaxalone should be administered with great care to patients with pre-existing liver damage. Serial liver function studies should be performed in these patients.
False-positive Benedict’s tests, due to an unknown reducing substance, have been noted. A glucose-specific test will differentiate findings.
Taking SKELAXIN with food may enhance general CNS depression; elderly patients may be especially susceptible to this CNS effect. (See CLINICAL PHARMACOLOGY: Pharmaco*kinetics and PRECAUTIONS: Information for Patients).
Information for Patients
SKELAXIN may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol or other CNS depressants.
Drug Interactions
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of metaxalone has not been determined.
Pregnancy
Reproduction studies in rats have not revealed evidence of impaired fertility or harm to the fetus due to metaxalone. Post marketing experience has not revealed evidence of fetal injury, but such experience cannot exclude the possibility of infrequent or subtle damage to the human fetus. Safe use of metaxalone has not been established with regard to possible adverse effects upon fetal development. Therefore, metaxalone tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgement of the physician the potential benefits outweigh the possible hazards.
Nursing Mothers
It is not known whether this drug is secreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.
Pediatric Use
Safety and effectiveness in children 12 years of age and below have not been established.
- Adverse Reactions
The most frequent reactions to metaxalone include:
CNS: drowsiness, dizziness, headache, and nervousness or “irritability”;
Digestive: nausea, vomiting, gastrointestinal upset.
Other adverse reactions are:
Immune System: hypersensitivity reaction, rash with or without pruritus;
Hematologic: leukopenia; hemolytic anemia;
Hepatobiliary: jaundice.
Though rare, anaphylactoid reactions have been reported with metaxalone.
- Overdosage
Deaths by deliberate or accidental overdose have occurred with metaxalone, particularly in combination with antidepressants, and have been reported with this class of drug in combination with alcohol.
When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratory failure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.
Treatment - Gastric lavage and supportive therapy. Consultation with a regional poison control center is recommended.
- Dosage and Administration
The recommended dose for adults and children over 12 years of age is one 800 mg tablet three to four times a day.
- How Supplied
SKELAXIN (metaxalone) is available as an 800 mg oval, scored pink tablet inscribed with 8667 on the scored side and “S” on the other. Available in bottles of:
15 (NDC 21695-123-15)
30 (NDC 21695-123-30)
60 (NDC 21695-123-60)
90 (NDC 21695-123-90)
Store at Controlled Room Temperature, between 15°C and 30°C (59°F and 86°F).
Rx Only
- Distributed by:
King Pharmaceuticals, Inc., Bristol, TN 37620
- Manufactured by:
Mallinckrodt Inc., Hobart, NY 13788
Prescribing Information as of April 2007.
Repackaged by:
Rebel Distributors Corp
Thousand Oaks, CA 91320
- Principal Display Panel
- INGREDIENTS AND APPEARANCE
SKELAXIN
metaxalone tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:21695-123(NDC:60793-136) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Metaxalone (UNII: 1NMA9J598Y) (Metaxalone - UNII:1NMA9J598Y) Metaxalone 800mg Product Characteristics Color PINK Score 2 pieces Shape OVAL Size 20mm Flavor Imprint Code 8667;S Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:21695-123-15 15 in 1 BOTTLE 2 NDC:21695-123-30 30 in 1 BOTTLE 3 NDC:21695-123-60 60 in 1 BOTTLE 4 NDC:21695-123-90 90 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA013217 08/13/1962 Labeler -Rebel Distributors Corp(118802834)
Establishment Name Address ID/FEI Business Operations Rebel Distributors Corp 118802834 RELABEL, REPACK
View All Sections
Find additional resources
(also available in the left menu)
Safety
Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk
Related Resources
Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary
More Info on this Drug
View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!
View Labeling Archives for this drug
SKELAXIN- metaxalone tablet
Number of versions: 1
| Published Date (What is this?) | Version | Files |
|---|---|---|
| Jan 13, 2011 | 1 (current) | download |
RxNorm
SKELAXIN- metaxalone tablet
| RxCUI | RxNorm NAME | RxTTY | |
|---|---|---|---|
| 1 | 351254 | metaxalone 800 MG Oral Tablet | PSN |
| 2 | 351254 | metaxalone 800 MG Oral Tablet | SCD |
| 3 | 352277 | Skelaxin 800 MG Oral Tablet | PSN |
| 4 | 352277 | metaxalone 800 MG Oral Tablet [Skelaxin] | SBD |
| 5 | 352277 | Skelaxin 800 MG Oral Tablet | SY |
Get Label RSS Feed for this Drug
SKELAXIN- metaxalone tablet
To receive this label RSS feed
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=cb47d76e-a7e3-4bac-8074-8d7e95c6a6eb
To receive all DailyMed Updates for the last seven days
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/rss.cfm
What will I get with the DailyMed RSS feed?
DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.
DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.
How to discontinue the RSS feed
If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.
Why is DailyMed no longer displaying pill images on the Search Results and Drug Info pages?
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels.
We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.
NDC Codes
SKELAXIN- metaxalone tablet
If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such.
| NDC | |
|---|---|
| 1 | 21695-123-15 (inactivated) |
| 2 | 21695-123-30 (inactivated) |
| 3 | 21695-123-60 (inactivated) |
| 4 | 21695-123-90 (inactivated) |
